Trial Profile
Effects of Everolimus (Certican) on cardiac hypertrophy and carotid atherosclerosis after kidney transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Basiliximab; Mycophenolate sodium; Prednisone; Tacrolimus
- Indications Carotid artery diseases; Left ventricular hypertrophy; Renal transplant rejection
- Focus Pharmacodynamics
- Sponsors Novartis
- 03 May 2017 Results presented at the 2017 American Transplant Congress
- 03 May 2017 Status changed from recruiting to completed, according to the results presented at the 2017 American Transplant Congress
- 17 Feb 2014 New trial record